Insmed Incorporated
INSM
#904
Rank
$27.164 B
Marketcap
United States
Country
$124.39
Share price
-6.17%
Change (1 day)
-15.32%
Change (1 year)
Categories
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen…
Key Metrics
Trailing P/E
—
Forward P/E
161.74
EPS (TTM)
$-4.17
Forward EPS
$0.77
Price / Book
35.73
EV / EBITDA
-33.5x
Beta
0.82
Dividend Yield
—
Return on Equity
-87.22%
Return on Assets
-22.17%
Debt / Equity
97.65
Current Ratio
3.72
Gross Margin
83.45%
Operating Margin
-23.81%
Net Profit Margin
-76.94%
Free Cash Flow
$-571,815,616
Charts
Price history and financial performance over time.
Price & Market Cap
Aug 19 – Sep 17
-5.11%
Source: Yahoo Finance daily closes. Market cap uses the closest quarterly shares-outstanding filing for each date.
Revenue & Net Income
Annual · USD
RevenueNet Income
Latest Revenue$606.423M
Latest Net Income$-1,276,775,000
Reporting periods4
Source: Yahoo Finance annual income statements. Year is the fiscal-year end. Most recent period may be trailing-twelve-month (TTM) until the next 10-K is filed.
Compare Insmed Incorporated with competitors
Side-by-side market cap, revenue, and financial comparison.
Latest News
Latest News
INSM
No recent news available. Set FINNHUB_API_KEY to enable news.
